N-Acetyl Selank
NootropicNA Selank — Synthetic Peptide
Overview
N-Acetyl Selank is a chemically modified variant of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) incorporating N-terminal acetylation. Selank itself is a Russian-developed, approved synthetic heptapeptide derived from the immunomodulatory peptide tuftsin. The acetyl group is added to the N-terminus to reduce degradation by aminopeptidases, theoretically extending the active plasma half-life compared to the parent compound.
N-Acetyl Selank has no independent published research — all mechanistic assumptions are extrapolated directly from the well-characterized Selank literature. It is available through research peptide vendors and is not approved for clinical use in any jurisdiction. It should be distinguished from N-Acetyl Selank Amidate (Adalank), which incorporates both N-terminal acetylation and C-terminal amidation.
Mechanism of Action
The mechanism of N-Acetyl Selank is assumed to mirror that of unmodified Selank, with enhanced metabolic stability conferred by the acetyl cap:
**GABAergic modulation** is the primary anxiolytic mechanism. Selank indirectly influences GABAergic neurotransmission by altering gene expression of GABA-A receptor subunits and GABA synthesis enzymes (GAD), rather than directly binding the GABA-A receptor. This indirect mechanism avoids the allosteric potentiation that produces sedation and tolerance with benzodiazepines.
**Immunomodulatory activity** derives from the tuftsin-derived Thr-Lys-Pro-Arg tetrapeptide core, which stimulates phagocytosis and modulates cytokine production. In rat brain, Selank modulates expression of interleukins, chemokines, and their receptors — a neuroimmune interaction relevant to neuroinflammation-linked cognitive decline.
**Enkephalin system engagement:** Selank inhibits enkephalin-degrading enzymes, elevating endogenous opioid peptide levels and contributing to anxiolytic and mood-stabilizing effects.
The N-terminal acetyl group blocks aminopeptidase cleavage, which is the primary route of Selank degradation. This modification is expected to prolong the biological activity of the active peptide without altering receptor engagement.
Research Dosing
N-acetylation is theorized to improve enzymatic stability relative to unmodified Selank. No independent clinical data exists specifically for N-Acetyl Selank. Dosing extrapolated from approved Selank protocols.
Less common than intranasal. Same mechanistic assumptions as Selank apply; no independent human safety data.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.
Published Studies
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova A, Sharova EV, Kliashchenko GI, et al. — Frontiers in Pharmacology, 2016
Demonstrated that Selank modulates expression of genes encoding GABA-A receptor subunits, GABA transaminase, and glutamic acid decarboxylase in rat hippocampus. N-Acetyl Selank is mechanistically extrapolated from this parent compound research; no independent studies of the acetylated form exist.
PMID: 26924987 →Selank, a novel tuftsin analog, regulates the expression of genes related to the immune response in rat brain
Andreeva LA, Nesmeyanova NA, et al. — Doklady Biological Sciences, 2010
Showed Selank modulates 36 genes involved in immune regulation in rat brain, supporting the anxiolytic and immunomodulatory dual mechanism. N-Acetyl Selank is presumed to share this mechanism with enhanced enzymatic stability.